With ELEVECTA®, CEVEC has taken a unique approach based on producer cell lines, which have all necessary elements for AAV production stably integrated in one cell. ELEVECTA® bridges the production gap of today’s AAV manufacturing processes by enabling efficient, high-performance AAV production from one cell line in consistent quality, avoiding every transfection step, expensive transfection reagents and cGMP-grade plasmids. The technology can easily be implemented in bioprocess development and large-scale GMP manufacturing facilities running standard suspension bioreactor equipment widely used in industry for monoclonal antibody and recombinant protein production. ELEVECTA® elevates AAV manufacturing to the next level.
